This Document can be made available in alternative formats upon request

1.4

1.5

1.6

1.7

1.8

1.9

1.10

1.11

1.12

1.13

1.14

1.15

State of Minnesota

HOUSE OF REPRESENTATIVES

NINETY-FIRST SESSION

H. F. No. 3907

02/27/2020 Authored by Cantrell and Schomacker

The bill was read for the first time and referred to the Committee on Health and Human Services Policy

1.1 A bill for an act

relating to human services; requiring the commissioner of human services to develop a process to identify and report 340B drugs at point of sale.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

Section 1. ENCOUNTER REPORTING OF 340B DRUGS.

(a) By January 1, 2021, the commissioner of human services, in consultation with representatives of federally qualified health centers, as defined in Minnesota Statutes, section 145.9269, subdivision 1, shall develop a process to identify and report at point of sale the 340B drugs that are dispensed to enrollees of managed care organizations served by federally qualified health centers in order to exclude 340B claims from the Medicaid drug rebate program. In developing this process, the commissioner shall work with federally qualified health centers, managed care organizations, and contracted pharmacies to ensure that 340B entities are allowed to maximize the 340B program and the 340B program drug discounts when 340B entities utilize contract pharmacies for patients enrolled in the prepaid medical assistance program, while ensuring that duplicate discounts for these drugs do not occur.

(b) The commissioner shall inform the chairs and ranking minority members of the

1.16 (b) The commissioner shall inform the chairs and ranking minority members of the
1.17 legislative committees with jurisdiction over health and human services policy and finance
1.18 of the process developed under paragraph (a), or if applicable, the reasons why this process
1.19 could not be developed as required.

Section 1.